Birth Control and Hair Loss: What to Know About Hormonal Contraceptives
Hormonal contraceptives sit in a unique place on the drug-induced hair-loss list because they can move hair in either direction. The right combination can quiet androgen-driven thinning and improve density over time. The wrong one for a given person can accelerate shedding. And the transitions, starting or stopping, can each trigger a telogen-effluvium shed that has nothing to do with whether the formulation was a good fit.
What follows is a practical look at how the math works: how progestins differ from one another, which transitions trigger shedding, how IUDs compare with pills, and how to have a productive conversation with a prescriber when hair is part of the calculation.
The two levers: estrogen and progestin
Combined oral contraceptives contain two active hormones. The estrogen component (almost always ethinyl estradiol in the United States) raises sex hormone binding globulin (SHBG), a protein that ties up circulating testosterone and reduces the amount of free, bioactive androgen reaching the hair follicle. Higher SHBG generally means less androgen pressure on follicles, which can help female pattern hair loss, acne, and hirsutism.
The progestin component is more variable. Progestins are synthetic versions of progesterone, and they differ widely in how strongly they bind to androgen receptors. Some progestins are intrinsically androgenic; some are essentially neutral; and a few are anti-androgenic, meaning they block androgen receptors directly.
The net effect on hair depends on the balance of these two components and on the individual user's underlying hair biology. A combined pill with anti-androgenic progestin and standard estrogen tends to be hair-friendly. A progestin-only formulation with a more androgenic progestin can be the opposite.
Where each progestin sits on the androgenic scale
The progestins commonly used in the United States fall on a rough spectrum from most androgenic to least or even anti-androgenic. Among the more androgenic options, the older 19-nortestosterone derivatives such as norethindrone (used in many progestin-only pills and some combined formulations) and levonorgestrel (used in combined pills and the levonorgestrel IUD) have measurable androgen-receptor activity. Closer to neutral sit norgestimate and desogestrel, both common in combined pills, with mild androgenic activity that is often offset by the estrogen in the same formulation. On the anti-androgenic end are drospirenone (a derivative of spironolactone) and dienogest, both of which actively block androgen-receptor signaling.
Cyproterone acetate is strongly anti-androgenic and is sometimes used in combined pills outside the United States, less often available domestically.
For a patient with androgenetic alopecia or with PCOS, a combined pill containing drospirenone or another anti-androgenic progestin is generally hair-friendlier than one containing levonorgestrel or norethindrone. This is not the only factor in choosing a contraceptive (clot risk, bleeding pattern, cost, and other side effects all matter), but it is a real one and worth raising with the prescriber.
Starting a new hormonal contraceptive can trigger a shed
The most common pattern is a telogen effluvium that starts about two to three months after beginning a new contraceptive and runs for several months. This is a classic medication-related telogen effluvium and typically resolves on its own as the hair cycle resynchronizes. The shedding is diffuse over the whole scalp rather than concentrated at the crown or part line.
Whether this happens, and how severe it is, varies widely. Many people start a new contraceptive without any hair change. Others experience a noticeable shed and then return to baseline within six to twelve months. The shed itself is not a sign that the formulation is the wrong one; it is a sign that the hair cycle has been perturbed.
A more concerning pattern is shedding that does not stabilize within nine to twelve months, or shedding that has a distinctly patterned distribution. That picture should be evaluated for an unmasked androgenetic pattern or for another contributor such as thyroid dysfunction, low ferritin, or a recent illness.
Stopping a hormonal contraceptive can also trigger a shed
This catches many users by surprise. "Post-pill" shedding is a recognized phenomenon: ending a combined contraceptive removes the SHBG-raising effect of ethinyl estradiol, briefly increasing free androgen exposure at the follicle. The shed typically appears two to four months after stopping and follows the same telogen-effluvium time course.
For most people the post-pill shed is self-limited and density returns within six to twelve months. For people with a genetic predisposition to androgenetic alopecia, stopping the pill can be when patterned thinning becomes visible for the first time. The contraceptive was masking it, and the underlying biology was always there.
Either way, the right framing is that hormonal contraceptives can be hair-active in both directions, and any transition (on, off, or between formulations) is a potential trigger.
How IUDs compare
The hormonal contraceptive landscape now includes options that bypass the systemic estrogen-progestin balance entirely.
Copper IUDs (such as Paragard) are nonhormonal. They do not change circulating androgens, SHBG, or the hair cycle, and reports of hair loss are largely confined to standard post-childbirth or post-procedure telogen effluvium that would have happened anyway.
Levonorgestrel IUDs (such as Mirena, Kyleena, Liletta, Skyla) release a low dose of levonorgestrel locally in the uterus. Systemic exposure is much lower than with a levonorgestrel-containing pill, but it is not zero, and a subset of users report hair shedding after IUD placement that mirrors the timing of a telogen effluvium.
For patients with strong hair concerns who still want long-acting contraception, the copper IUD is the most hair-neutral option.
Implants, injections, and rings
The contraceptive implant (etonogestrel, Nexplanon) and the injection (medroxyprogesterone acetate, Depo-Provera) are progestin-only with more systemic exposure than the hormonal IUDs. Both have hair-shedding reports, and Depo-Provera in particular has a longer washout that complicates timing if a user wants to switch. The contraceptive ring (ethinyl estradiol and etonogestrel) has a hair profile generally similar to a combined oral contraceptive with the same hormones.
A practical decision framework
When hair is part of the contraceptive decision, the conversation usually centers on a few questions:
Is the hair loss patterned or diffuse? Patterned thinning at the crown or part line suggests an underlying androgenetic component, and a contraceptive with an anti-androgenic progestin is often preferred when contraception is needed. Diffuse shedding after a recent change suggests a telogen effluvium that may resolve on its own.
Has anything else changed? Recent childbirth, significant weight changes, new diagnosis of thyroid disease, or a course of another medication can all contribute. A basic workup (ferritin, TSH, free T4, vitamin D, B12) is often worth running before attributing the shed to contraception.
What other features matter? Bleeding pattern, clot risk, mood, acne, cost, and preference for a pill vs. a long-acting method all play in. Hair is one factor among several.
What is the time horizon? A telogen-effluvium shed within the first six months of a change is usually self-limited. Persistent shedding at nine to twelve months is the marker for re-evaluation.
The prescribing clinician (gynecologist, primary care, or telehealth provider) is the right person to weigh these together. If a switch is being considered specifically to help hair, the typical move is from a more androgenic progestin to an anti-androgenic one, with a planned re-check at three to six months.
When the picture is patterned androgenetic alopecia
If the hair loss is concentrated along the part line and crown, has been progressing for years, or has a family history behind it, the most likely diagnosis is female pattern hair loss rather than contraceptive-induced shedding. In that case the contraceptive choice still matters (an anti-androgenic option is often a useful piece of the plan), but the core treatment involves evidence-based options for women including topical minoxidil and, in some cases, oral medications discussed with a clinician. The hormonal causes overview covers the broader picture.
Considering medical assessment
Hair changes around contraceptive transitions are common, and they are also often misattributed. The most useful next step is a medical assessment that looks at the timing of the change, the pattern of the loss, and any other contributors. A clinician can help distinguish a self-limited shed from an underlying female pattern, and can coordinate with the prescribing gynecologist if a contraceptive switch is part of the plan. The Curekey assessment is online and free to start. Visit /your-plan-2 or read about how it works for more.
Related reading
- Drug-induced hair loss overview
- Hair loss in women
- Female pattern hair loss
- Hormonal causes of hair loss
- Postpartum hair loss
- PCOS and hair loss
- Medication-related hair loss
